menu
    • menu

    Company profile for RemeGen

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At RemeGen, Ltd., a leading biotech innovator in China, we believe biologics are the future of medicine—and we’re ready to take our therapeutic innovations to the global stage. We’re aligning our investments in scientific research, manufacturing and commercialization to change the way cancer, autoimmune and eye diseases are treated.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RemeGenChina Flag
    Country
    Country
    China
    Address
    Address
    58 Middle Beijing Road, Yantai Economic and Technological Development Zone, Ya...
    Telephone
    Telephone
    (86) 535-6113513
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://remegen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Telitacicept Shows Long-Term Efficacy In 48-Week China Ph 3 Data
    Telitacicept Shows Long-Term Efficacy In 48-Week China Ph 3 Data

    29 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/29/3176649/0/en/Telitacicept-Demonstrates-Sustained-Efficacy-and-Favorable-Safety-Profile-in-48-Week-China-Phase-3-Open-Label-Extension-Generalized-Myasthenia-Gravis-Data.html

    GLOBENEWSWIRE
    29 Oct 2025
    Share Share
    Vor Bio to Host Webcast on China Ph3 Telitacicept Sjögren’s Data
    Vor Bio to Host Webcast on China Ph3 Telitacicept Sjögren’s Data

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3171527/0/en/Vor-Bio-to-Host-Webcast-on-Late-Breaking-China-Phase-3-Telitacicept-Data-in-Primary-Sj%C3%B6gren-s-Disease.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share
    Vor Bio Presents China Phase 3 Iga Nephropathy Study At ASN
    Vor Bio Presents China Phase 3 Iga Nephropathy Study At ASN

    17 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/17/3168567/0/en/Vor-Bio-Announces-Late-Breaking-Oral-Presentation-of-China-Phase-3-IgA-Nephropathy-Clinical-Study-at-American-Society-of-Nephrology-s-Kidney-Week-2025.html

    GLOBENEWSWIRE
    17 Oct 2025
    Share Share
    Vor Bio Publishes China Phase 3 Telitacicept Study In Lupus
    Vor Bio Publishes China Phase 3 Telitacicept Study In Lupus

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167846/0/en/Vor-Bio-Announces-Publication-of-China-Phase-3-Study-of-Telitacicept-in-Systemic-Lupus-Erythematosus-in-The-New-England-Journal-of-Medicine.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    Telitacicept Phase III Data In Sjögren's Syndrome At 2025 ACR
    Telitacicept Phase III Data In Sjögren's Syndrome At 2025 ACR

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/2025-acr-abstract-released-exciting-data-from-telitacicepts-phase-iii-clinical-study-in-sjogrens-syndrome-in-china-302582947.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Vor Bio Presents Phase 3 Sjögren's Disease Study Poster At ACR
    Vor Bio Presents Phase 3 Sjögren's Disease Study Poster At ACR

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3157572/0/en/Vor-Bio-Announces-Late-Breaking-Poster-Presentation-of-Phase-3-Primary-Sj%C3%B6gren-s-Disease-Clinical-Study-at-ACR-Convergence-2025.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search